



**Congress Presidents**  
Axel Hauschild, Kiel, Germany  
Claus Garbe, Tuebingen, Germany

**HYBRID  
EVENT**

# 14<sup>th</sup> European Post-Chicago Melanoma/Skin Cancer Meeting

**Results and Interpretations of ASCO Presentations 2024:  
Interdisciplinary Global Conference on News in Melanoma/Skin Cancer**

**Preliminary Program** (updated: 23/04/2024)

**June 27<sup>th</sup>–28<sup>th</sup>, 2024**  
**Munich, Germany**  
**Hilton Hotel Munich Park**

<https://european-post-chicago-meeting.org>



Under the auspices of the  
European Association  
of Dermato-Oncology

# CONTENT

---

»» WELCOME MESSAGE 01

---

»» PROGRAM AT A GLANCE 02

»» PROGRAM 04

Thursday, June 27<sup>th</sup>, 2024 04

Friday, June 28<sup>th</sup>, 2024 07

---

»» CONGRESS FACULTY 10

---

»» SATELLITE SYMPOSIA OVERVIEW 14

»» FLOOR PLAN 16

---

»» GENERAL INFORMATION 18

»» SPONSORS 20

# WELCOME MESSAGE

Dear colleagues and friends,

The first Post-Chicago Meeting on Melanoma /Skin Cancer took place 2011. The 13<sup>th</sup> edition in 2023 **was held as a hybrid meeting with more than 400 attendees on-site and another 350 virtually**. The interactive congress offers a comprehensive overview of all new developments in melanoma diagnostics and therapy and direct communication with the world's leading experts in these fields.

**The aim of the Interdisciplinary Global Conference on News in Melanoma/Skin Cancer in Munich is to grant a deep overall insight into the development of new drugs for melanoma and other cutaneous malignancies.** The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant.

International key opinion leaders on melanoma will be invited to give an overview throughout specified presentations, to present the latest clinical trial results, and to discuss exciting new drugs with the audience. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities in Germany.

**We welcome you in Munich and online!**



Axel Hauschild, MD  
Congress President



Claus Garbe, MD  
Congress President

# PROGRAM AT A GLANCE

## THURSDAY, JUNE 27<sup>th</sup>, 2024

	BALLROOM*	RUMFORD
8:00	Opening of the conference <b>SYMPOSIUM I</b> My personal highlights at ASCO 2024	
9:00	<b>KEYNOTE LECTURE I</b>	
10:00	<b>SATELLITE SYMPOSIUM I</b>	
11:00	BREAK <b>SATELLITE SYMPOSIUM II</b>	
12:00	<b>SYMPOSIUM II</b>	<b>PARALLEL SYMPOSIUM I</b> Adverse event management of targeted and immunotherapies.
13:00	BREAK	
14:00	<b>SATELLITE SYMPOSIUM III</b>	
15:00	<b>SYMPOSIUM III</b> The role of gut microbiome for immunooncology.	<b>PARALLEL SYMPOSIUM II</b> Real world evidence studies from registries.
16:00	BREAK <b>SYMPOSIUM IV</b> Bispecific T-cell engagers (BTE) in cutaneous and uveal melanomas (unrestricted Educational Grant Immunocore)	
17:00	<b>SYMPOSIUM V</b> Controversy: Is neoadjuvant or perioperative ICI already standard of care?	<b>PARALLEL SYMPOSIUM III</b> Cutaneous T-cell lymphoma (CTCL)
18:00		
19:00		

# FRIDAY, JUNE 28<sup>th</sup>, 2024

	BALLROOM*	RUMFORD
8:00	<b>SYMPOSIUM VI</b> Adjuvant treatment of melanoma	<b>PARALLEL SYMPOSIUM IV</b> Interactive Discussion of complex melanoma cases
9:00		<b>PARALLEL SYMPOSIUM V</b> Interactive Discussion of complex non-melanoma cases
10:00	<b>SATELLITE SYMPOSIUM IV</b>	
	BREAK	
11:00	<b>KEYNOTE LECTURES II + III</b>	
12:00	<b>SATELLITE SYMPOSIUM V</b>	
13:00	BREAK	
14:00	<b>SYMPOSIUM VII</b> Intralesional therapies for melanoma and NMSC	<b>PARALLEL SYMPOSIUM VI</b> Innovative therapies for orphan diseases
15:00	<b>KEYNOTE LECTURES IV</b>	
	BREAK	
	<b>SATELLITE SYMPOSIUM VI</b>	
16:00	<b>SATELLITE SYMPOSIUM VII</b>	
17:00	<b>SYMPOSIUM VIII</b> What's new in NMSC? Publication highlights from the last 12 months	
	<b>CLOSING REMARKS</b>	
18:00		
19:00		

# THURSDAY, JUNE 27<sup>th</sup>, 2024

08:00

BALLROOM

## OPENING OF THE CONFERENCE

AXEL HAUSCHILD, KIEL, GERMANY

08:10–09:30

BALLROOM

## SYMPOSIUM I

My personal highlights at ASCO 2024

CHAIRPERSONS: PAOLO ASCIERTO, NAPLES, ITALY  
MARIO MANDALA, PERUGIA, ITALY

08:10–08:40 ... in melanoma

**Sapna Patel, Houston, USA**

08:50–09:20 ... in non-melanoma skin cancer

**Selma Ugurel, Essen, Germany**

09:30–10:00

BALLROOM

## KEYNOTE LECTURE I

CHAIRPERSON: REINHARD DUMMER, ZURICH, SWITZERLAND

Can Precision Oncology Improve Survival?

**Olivier Michielin, Geneva, Switzerland**

10:00–10:45

BALLROOM

## SATELLITE SYMPOSIUM I

(SEE PAGE 14)

10:45–11:15

## BREAK

11:15–12:00

BALLROOM

## SATELLITE SYMPOSIUM II

(SEE PAGE 14)

12:00–13:00

BALLROOM

## SYMPOSIUM II

Which vaccines work and which not?

CHAIRPERSONS: CAROLINE ROBERT, PARIS, FRANCE  
JÜRGEN BECKER, ESSEN, GERMANY

12:00–12:15 History of tumor vaccination till 2022.

**Paolo Ascierto, Naples, Italy**

12:20–12:35 Personalized tumor vaccines.

**NN**

12:40–12:55 Non personalized tumor vaccines.

**Jürgen Becker, Essen, Germany**

# THURSDAY, JUNE 27<sup>th</sup>, 2024

12:00–13:00

RUMFORD

## PARALLEL SYMPOSIUM I

Adverse event management of targeted and immunotherapies.

CHAIRPERSONS: RALF GUTZMER, MINDEN, GERMANY  
CELESTE LEBBÉ, PARIS, FRANCE

12:00–12:15 Investigator-driven guidelines for  
TT adverse event management.

**Christoph Hoeller, Vienna, Austria**

12:20–12:35 Investigator driven guidelines for  
IO adverse event management.

**Ralf Gutzmer, Minden, Germany**

12:40–12:55 Chronic immune related adverse events.

**Celeste Lebbé, Paris, France**

13:00–14:00

BREAK

14:00–15:00

BALLROOM

## SATELLITE SYMPOSIUM III

(SEE PAGE 14)

15:00–16:00

BALLROOM

## SYMPOSIUM III

The role of gut microbiome for immunooncology.

CHAIRPERSONS: CHRISTIAN BLANK, AMSTERDAM, THE NETHERLANDS  
JESSICA HASSEL, HEIDELBERG, GERMANY

15:00–15:13 Microbiome as a prognostic or predictive biomarker?

**Caroline Robert, Paris, France**

15:15–15:28 Fecal microbiota transplantation for PD-1 refractory patients?

**Hussein Tawbi, Houston, USA**

15:30–15:43 Diets and/or probiotica to improve the therapeutic outcomes?

**Sapna Patel, Houston, USA**

15:45–16:00 Discussion

15:00–17:15

RUMFORD

## PARALLEL SYMPOSIUM II

Real world evidence studies from registries.

CHAIRPERSONS: LIDIJA KANDOLF, BELGRADE, SERBIA  
JOSEP MALVEHY, BARCELONA, SPAIN  
MICHAEL WEICHENTHAL, KIEL, GERMANY

16:00–16:15

BREAK

# THURSDAY, JUNE 27<sup>th</sup>, 2024

16:15–17:15

BALLROOM

## SYMPOSIUM IV

Bispecific T-cell engagers (BTE) in cutaneous and uveal melanomas (unrestricted Educational Grant Immunocore)

CHAIRPERSONS: OMID HAMID, LOS ANGELES, USA  
ALEXANDER EGGERMONT, UTRECHT,  
THE NETHERLANDS

16:15–16:30 Tebentafusp  
**Jessica Hassel, Heidelberg, Germany**

16:35–16:50 PRAME-directed immunotherapies  
**Omid Hamid, Los Angeles, USA**

16:55–17:10 What about other BTE?  
**Reinhard Dummer, Zurich, Switzerland**

17:15–18:15

BALLROOM

## SYMPOSIUM V

Controversy: Is neoadjuvant or perioperative ICI already standard of care?

CHAIRPERSONS: AXEL HAUSCHILD, KIEL, GERMANY  
CLAUS GARBE, TUEBINGEN, GERMANY

17:15–17:30 Pro  
**Christian Blank, Amsterdam, the Netherlands**

17:30–17:45 Contra  
**Dirk Schadendorf, Essen, Germany**

17:45–18:15 Panel Discussion

17:15–18:15

RUMFORD

## PARALLEL SYMPOSIUM III

Cutaneous T-cell lymphoma (CTCL)

CHAIRPERSONS: CLAUS-DETLEV KLEMKE, KARLSRUHE, GERMANY  
EMMANUELLA GUENOVA, LAUSANNE, SWITZERLAND

17:15–17:30 Medical needs in CTCL  
**Claus-Detlev Klemke, Karlsruhe, Germany**

17:35–17:50 First-line treatment: standards and trials  
**Edgar Dippel, Ludwigshafen, Germany**

17:55–18:10 Later-line treatment: standards and trials  
**Emmanuella Guenova, Lausanne, Switzerland**



# FRIDAY, JUNE 28<sup>th</sup>, 2024

08:00–10:00

BALLROOM

## SYMPOSIUM VI

### Adjuvant treatment of melanoma

CHAIRPERSONS: PETER MOHR, BUXTEHUDE, GERMANY  
MERRICK I. ROSS, HOUSTON, USA

08:00–08:20 Current standards in stage II and III  
**Vernon Sondak, Tampa, USA**

08:25–08:45 Current trials in stage II and III  
**Peter Mohr, Buxtehude, Germany**

08:50–09:10 Should we treat stage IV NED patients post-surgery?  
**Merrick I. Ross, Houston, USA**

09:15–09:35 Biomarker driven treatment decisions: the future?  
**Christoffer Gebhardt, Hamburg, Germany**

09:40–09:55 No future for adjuvant treatment?  
**Christian Blank, Amsterdam, the Netherlands**

08:00–09:00

RUMFORD

## PARALLEL SYMPOSIUM IV

### Interactive Discussion of complex melanoma cases

CHAIRPERSONS: MARIO MANDALA, PERUGIA, ITALY  
RAFAEL SCHMERLING, SAO PAULO, BRAZIL  
RICARDO VIEIRA, COIMBRA, PORTUGAL  
TERESA AMARAL, TUEBINGEN, GERMANY

09:00–10:00

RUMFORD

## PARALLEL SYMPOSIUM V

### Interactive Discussion of complex non-melanoma cases

CHAIRPERSONS: RODRIGO MUNHOZ, SAO PAULO, BRAZIL  
ZELJKO MIJUSKOVIC, BELGRADE, SERBIA  
FRIEDEGUND MEIER, DRESDEN, GERMANY  
ULRIKE LEITER-STOEPPE, TUEBINGEN, GERMANY

10:00–10:45

BALLROOM

## SATELLITE SYMPOSIUM IV

(SEE PAGE 15)

10:45–11:00

## BREAK

# FRIDAY, JUNE 28<sup>th</sup>, 2024

11:00–12:00

BALLROOM

## KEYNOTE LECTURE II + III

CHAIRPERSONS: HUSSEIN TAWBI, HOUSTON, USA  
CHRISTOPH HOELLER, VIENNA, AUSTRIA

11:00–11:30 Tumor infiltrating lymphocytes: ready for prime time?  
**Omid Hamid, Los Angeles, USA**

11:30–12:00 Multimodal management of brain metastasis  
**Paul Lorigan, Manchester, United Kingdom**

12:00–13:00

BALLROOM

## SATELLITE SYMPOSIUM V

(SEE PAGE 15)

13:00–13:45

## BREAK

13:45–14:45

BALLROOM

## SYMPOSIUM VII

Intralesional therapies for melanoma and NMSC

CHAIRPERSONS: RODRIGO MUNHOZ, SAO PAULO, BRAZIL  
ULRIKE LEITER-STÖPPKE, TUEBINGEN, GERMANY

13:45–14:00 Neoadjuvant T-VEC for melanoma and non-melanoma skin cancer  
**Reinhard Dummer, Zurich, Switzerland**

14:05–14:20 CERPASS: results on randomized cemiplimab +/- RP1 in CSCC  
**Axel Hauschild, Kiel, Germany**

14:25–14:40 The future of intralesional treatment  
**Thomas Eigentler, Berlin, Germany**

13:45–14:45

RUMFORD

## PARALLEL SYMPOSIUM VI

Innovative therapies for orphan diseases

CHAIRPERSONS: CHALID ASSAF, KREFELD, GERMANY  
DAGMAR VON BUBNOFF, LUEBECK, GERMANY

14:00–14:15 Tagraxofusp in blastic plasmacytoid dendritic cell neoplasm (BPDCN)  
**Chalid Assaf, Krefeld, Germany**

14:20–14:35 Lirentelimab in indolent systemic mastocytosis.  
**Dagmar von Bubnoff, Luebeck, Germany**

14:40–14:55 Selumetinib in children with neurofibromatosis type 1  
**Ines Brecht, Tuebingen, Germany**

# FRIDAY, JUNE 28<sup>th</sup>, 2024

14:45–15:05

BALLROOM

## KEYNOTE LECTURES IV

CHAIRPERSONS: OMID HAMID, LOS ANGELES, USA  
VERNON SONDAK, TAMPA, USA

14:45–15:05 Surgery in the era of effective systemic treatments  
**Alexander van Akkooi, Sydney, Australia**

15:05–15:20

## BREAK

15:20–15:50

BALLROOM

## SATELLITE SYMPOSIUM VI

(SEE PAGE 15)

15:50–16:20

BALLROOM

## SATELLITE SYMPOSIUM VII

(SEE PAGE 15)

16:20–17:20

BALLROOM

## SYMPOSIUM VIII

What's new in NMSC?

Publication highlights from the last 12 months

CHAIRPERSONS: KETTY PERIS, ROME, ITALY  
ALEXANDER STRATIGOS, ATHENS, GREECE

16:20–16:35 Basal cell carcinoma  
**Ketty Peris, Rome, Italy**

16:40–16:55 Squamous cell carcinoma  
**Alexander Stratigos, Athens, Greece**

17:00–17:15 Rare tumors  
**Markus Heppt, Erlangen, Germany**

17:20

## CLOSING REMARKS

**Claus Garbe, Tuebingen, Germany**

# CONGRESS FACULTY

## A

---

**Teresa Amaral, MD**

University Hospital Tuebingen  
Tuebingen, Germany

**Paolo Ascierto, MD**

National Cancer Institute IRCCS "Fondazione G. Pascale"  
Melanoma, Cancer Immunotherapy and  
Innovative Therapy Unit National Cancer Institute  
Naples, Italy

**Chalid Assaf, MD**

Helios Clinic Krefeld  
Krefeld, Germany

## B

---

**Jürgen Becker, MD**

West German Cancer Center (WTZ)  
German Cancer Research Center (DKFZ)  
University Duisburg-Essen  
Essen, Germany

**Christian Blank, MD**

Netherlands Cancer Institute Antoni van Leeuwenhoek  
Amsterdam, The Netherlands

**Ines Brecht, MD**

University Clinic for Pediatrics and Adolescent  
Medicine Tuebingen  
Tuebingen, Germany

## D

---

**Edgar Dippel, MD**

Dermatology clinic at Ludwigshafen Hospital  
Ludwigshafen, Germany

**Reinhard Dummer, MD**

University of Zurich  
Department of Dermatology University of Zurich  
Zurich, Switzerland

## E

---

**Alexander Eggermont, MD**

Princess Máxima Center for Pediatric Oncology  
Utrecht, The Netherlands

**Thomas Eigentler, MD**

Charité University Clinic Berlin  
Berlin, Germany

## G

---

**Claus Garbe, MD**

Eberhard Karls University  
Department of Dermatology  
Tuebingen, Germany

**Christoffer Gebhardt, MD**

University Hospital Hamburg-Eppendorf (UKE)  
Skin Cancer Center  
Hamburg, Germany

**Emmanuella Guenova, MD**

Hospital Beaumont Du Chuv  
Lausanne, Switzerland

**Ralf Gutzmer, MD**

University Hospital of the Ruhr University Bochum  
Department of Dermatology  
Johannes Wesling Medical Center Minden  
Minden, Germany

## H

---

**Omid Hamid, MD**

The Angeles Clinic and Research Institut  
Los Angeles, USA

**Jessica Hassel, MD**

University Hospital Heidelberg  
Heidelberg, Germany

**Axel Hauschild, MD**

University of Kiel  
Department of Dermatology  
Kiel, Germany

**Markus Heppt, MD**

University Hospital Erlangen  
Department of Dermatology  
Erlangen, Germany

**Christoph Hoeller, MD**

Medical University of Vienna  
Vienna, Austria

## K

---

**Lidija Kandolf, MD**

Military Medical Academy  
Department of Dermatology  
Medical Faculty  
Belgrade, Serbia

**Claus-Detlev Klemke, MD**

Hospital Karlsruhe  
Karlsruhe, Germany

## L

---

**Celeste Lebbé, MD**

Hospital Saint-Louis  
Department of Dermatology  
Paris, France

**Ulrike Leiter-Stoeppke, MD**

Center of Dermato-Oncology  
Department of Dermatology  
Tuebingen, Germany

**Paul Lorigan, MD**

The University of Manchester  
Manchester, United Kingdom

# CONGRESS FACULTY

## M

---

**Mario Mandala, MD**

University of Perugia  
Piazza dell'Università, 1  
Perugia, Italy

**Josep Malvehy, MD**

University of Barcelona  
Director of the Melanoma Unit  
Department of Dermatology  
Hospital Clinic of Barcelona  
Barcelona, Spain

**Friedegund Meier, MD**

University Clinic Dresden  
Dresden, Germany

**Olivier Michielin, MD**

University of Geneva  
Department of Oncology  
University Hospitals of Geneva  
Geneva, Switzerland

**Zeljko Mijuskovic, MD**

Dermatology Clinic for Goat Diseases  
Department of Dermatology  
Medical Faculty  
Military Medical Academy  
Belgrade, Serbia

**Peter Mohr, MD**

Elbe clinics  
Department of Dermatology  
Elbe Klinikum Buxtehude  
Head of Skin Cancer Center Buxtehude  
Buxtehude, Germany

## P

---

**Sapna Patel, MD**

University of Texas  
MD Anderson Cancer Centre  
Houston, United States

**Ketty Peris, MD**

Catholic University of Rome  
Rome, Italy

## R

---

**Caroline Robert, MD**

Gustave Roussy Institute  
Paris, France

**Merrick I. Ross, MD**

The University of Texas  
Houston, United States

## S

---

**Dirk Schadendorf, MD**  
University Hospital Essen  
Department of Dermatology  
Essen, Germany

**Rafael Schmerling, MD**  
Hospital Sao Paulo  
Sao Paulo, Brazil

**Vernon Sondak, MD**  
Moffitt Cancer Center  
Richard M. Schulze Family Foundation Outpatient  
Center at McKinley Campus  
Tampa, USA

**Alexander Stratigos, MD**  
Andreas Syngros Hospital  
Athens, Greece

## T

---

**Hussein Tawbi, MD**  
The University of Texas  
MD Anderson Cancer Center  
Houston, USA

## U

---

**Selma Ugurel, MD**  
University Hospital Essen  
Essen, Germany

## V

---

**Alexander van Akkooi, MD**  
Sydney, Australia

**Dagmar von Bubnoff, MD**  
University Clinic Schleswig Holstein  
Luebeck, Germany

**Ricardo Vieira, MD**  
Faculty of Medicine  
Centro Hospitalar e Universitário de Coimbra  
Coimbra, Portugal

## W

---

**Michael Weichenthal, MD**  
University of Kiel  
Department of Dermatology  
Kiel, Germany

# SATELLITE SYMPOSIA OVERVIEW

THURSDAY, JUNE 27<sup>nd</sup>, 2024

---

10:00–10:45 SATELLITE SYMPOSIUM I

**NOVARTIS** Gold Sponsor

**Yesterday, Today & Tomorrow: Long-Term Benefits with Targeted Therapy in Adjuvant Melanoma**

CHAIR: AXEL HAUSCHILD

---

11:15–12:00 SATELLITE SYMPOSIUM II

**BMS** Gold Sponsor

**IO-Combinations in Melanoma: How to Proceed – Less or More?**

CHAIR: CAROLINE ROBERT

11:15–11:20 Introduction

**Caroline Robert**

11:20–11:35 Lecture 1: „Less“: Update of the NADINA-study – Outcome and implications for clinical practice

**Christian Blank**

11:35–11:50 Lecture 2: „More“: Conventional IO-approaches – using the example of Opdualag in particular

**Dirk Schadendorf**

11:50–12:00 Discussion – All / audience

**Dirk Schadendorf**

---

14:00–15:00 SATELLITE SYMPOSIUM III

**MSD/MERCK** Platinum Sponsor

**Advancements in Early Melanoma: Integrating Recent Updates into Clinical Practice**

CHAIR: AXEL HAUSCHILD

14:00–14:05 Welcome and Opening Remarks

**Axel Hauschild**

14:05–14:20 Understanding risk of recurrence in early melanoma stages

**Peter Mohr**

14:20–14:40 Recent Advancements in the treatment of Early-Stage Melanoma: Overview of clinical evidence

**Dirk Schadendorf**

14:40–14:55 Clinical cases Q&A

**Merrick Ross**

14:55–15:00 Closing remarks

**Axel Hauschild**



## FRIDAY, JUNE 28<sup>nd</sup>, 2024

---

10:00–10:45 SATELLITE SYMPOSIUM IV

**PIERRE FABRE** Gold Sponsor

**Tailoring treatments in BRAF-mutant metastatic melanoma.  
One size does not fit all**

CHAIR: DIRK SCHADENDORF

10:00–10:06 Welcome and introduction

**Dirk Schadendorf**

10:06–10:36 Evolving treatment strategies in clinical practice: A case-based discussion

**Caroline Robert, Teresa Amaral**

10:36–10:44 From clinical trials to real-life practice:

Remaining unanswered questions

**Dirk Schadendorf**

10:44–10:45 Closing remarks

**Dirk Schadendorf**

---

12:00–13:00 SATELLITE SYMPOSIUM V

**REGENERON** Platinum Sponsor

**Evolving Perspectives on Treatment Roadmap for  
Advanced Non-melanoma Skin Cancer**

CHAIR: AXEL HAUSCHILD

12:00–12:01 Welcome and Introductions

**Axel Hauschild**

12:01–12:16 Emerging Therapeutic Avenues for Difficult-to-Treat

Advanced Cutaneous Squamous Cell Carcinoma

**Ketty Peris**

12:16–12:31 Mapping the Future of Immunotherapy in Advanced Cutaneous Squamous

Cell Carcinoma: Perspectives on Treatment Initiation and Duration

**Axel Hauschild**

12:31–12:46 Shifting Paradigms in the Treatment of Advanced Basal Cell Carcinoma

**Reinhard Dummer**

---

15:20–15:50 SATELLITE SYMPOSIUM VI

**PHILOGEN** Sponsor

---

15:50–16:20 SATELLITE SYMPOSIUM VII

Merck Bronze Sponsor


**Leveraging Real-World Evidence in Advanced Merkel  
Cell Carcinoma: Insights from Clinical Practice**

CHAIR: AXEL HAUSCHILD


# FLOOR PLAN

## HILTON MUNICH PARK

### ERDGESCHOSS/GROUND FLOOR



MEZZANINE



# GENERAL INFORMATION

## Cancellation Policy

Cancellations must be received in writing by May 11<sup>th</sup>, 2024. No refunds will be granted after that date. To cancel a registration, please send an email to [info@medconcept.org](mailto:info@medconcept.org) and include "European Post-Chicago Meeting 2024 Cancellation" in the subject line. A processing fee of 30 euros will be deducted from each canceled registration.

Substitutions (new ticket holders must come from the same institution) are possible and must be received in writing by June 16<sup>th</sup>, 2024. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to [info@medconcept.org](mailto:info@medconcept.org) and include "European Post-Chicago Meeting 2024 Substitution" in the subject line.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

## CME Credits

An application for CME accreditation will be made.

## How to receive your CME Credits

To receive your daily CME credits please scan yourself once a day at the registration desk. German participants must also register in the barcode list of the Bavarian Medical Association. To obtain the CME certificate, the official EACCME questionnaire must be filled out online. The link to the survey will be sent within 10 days after the congress.

## Congress Date

June 27<sup>th</sup>–June 28<sup>th</sup>, 2024

## Congress Organization



Gesellschaft für medizinische Projekte mbH  
Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany  
[info@medconcept.org](mailto:info@medconcept.org)  
[www.medconcept.org](http://www.medconcept.org)  
Phone +49 (0)3342 42689-30  
Fax +49 (0)3342 42689-40

## Congress Venue

HILTON MUNICH PARK, Am Tucherpark 7, 80538 Munich, Germany  
Phone: +49 (0)89 3845 0  
Fax: +49 (0)89 3845 2588  
E-Mail: [info.munich@hilton.com](mailto:info.munich@hilton.com)  
[www.munich-park.hilton.com](http://www.munich-park.hilton.com)

## Exhibition

A commercial exhibition will be held at the congress venue, close to the main rooms.

## Exhibition Opening Hours

Thursday, June 27<sup>th</sup>, 2024    07:30–18:30  
Friday, June 28<sup>th</sup>, 2024    07:30–18:00

## Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements with respect to health and travel insurance.

## Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

## Registration and Information Desk

The registration desk is situated at the ground floor of the Hilton Hotel to the right of the reception and in front of the meeting area entrance.

### Registration Desk Opening Hours

Wednesday, June 26<sup>th</sup>, 2024 16:00–18:00 (early check-in)

Thursday, June 27<sup>th</sup>, 2024 07:00–19:00

Friday, June 28<sup>th</sup>, 2024 07:30–18:00

## Registration Fees

Virtual packages and on-demand service is included in all ticket categories.

	Presence Tickets			Virtual Tickets
	Early Bird until May 1 <sup>st</sup> , 2024	Regular Fee until June 16 <sup>th</sup> , 2024	Late	
Full Delegate Ticket	400 euros	500 euros	600 euros	400 euros
EADO Members	300 euros	400 euros	500 euros	300 euros
Students/Nurses Ticket*	150 euros	200 euros	250 euros	150 euros
Eastern European Countries*	150 euros	200 euros	250 euros	150 euros
Residents*	150 euros	200 euros	250 euros	150 euros

\*Please upload proof of university or clinic for students/nurse ticket, and proof of residence in a european eastern country for reduced tickets of this category, during registration process.

# SPONSORS

## PLATINUM



**REGENERON**

## GOLD



## SILVER

**IMMUNOCORE**

## EXHIBITORS

**MERCK**



**Philogen**  
innovating targeting

**agenus**

MSD/Merck & Co. Inc. 130.000,00 € | Regeneron 130.000,00 € | Bristol-Myers Squibb 95.000,00 € | Novartis 95.000,00 € | Pierre Fabre 95.000,00 € | Immunocore 50.000,00 € | Merck 13.000,00 € | Replimune 12.600,00 € | Sun Pharma 16.200,00 € | Philogen 15.000,00 € | Agenus 5.000,00 €

# KOMPROMISSLOS<sup>#</sup> IN DER ADJUVANZ

**TAFINLAR® + MEKINIST®  
bei BRAF+-Melanom Stadium III:<sup>1,2</sup>**

- **SCHÜTZT**  
langfristig vor Rezidiven<sup>3</sup>
- **VERLÄSSLICH**  
im Sicherheitsprofil – auch  
über die Therapie hinaus<sup>3-7</sup>

**Im Einsatz für das Leben  
nach dem Melanom.**



# Das Melanom im Stadium III ist mit einem hohen Rezidiv- und Mortalitätsrisiko assoziiert. Dementsprechend muss die adjuvante Therapie mit den Patienten ausführlich besprochen werden. Die Entscheidung für eine Therapie erfordert Abwägungen bezüglich der verschiedenen Nebenwirkungsprofile, der bevorzugten Applikationsform und der individuellen Wirksamkeit in einem Arzt-Patienten-Gespräch.<sup>8,9</sup>

**Referenzen:**

1. Fachinformation Tafinlar®. 2. Fachinformation Mekinist®. 3. Dummer R et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020; 383:1139 - 1148. 4. Long GV et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017; 377: 1813 - 1823. 5. Atkinson V et al. Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. ESMO 2018, München. Poster 1251P. 6. Duong SL et al. Spätfolgen nach Immuntherapie. Onkologe. 2021; 27: 739 - 746. 7. Funck-Brentano E et al. Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma? Annales de Dermatologie et de Vénérologie. 2021; 148(3): 145 - 155. 8. Romano E et al. Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines. J Clin Onc. 2010; 28(18): 3042 - 3047. 9. Stege H et al. The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. J Clin Onc. 2021; 39: 537 - 552.



**Die Pflichtangaben finden Sie hier oder über den QR-Code:**

[https://www.novartis.com/de-de/sites/novartis\\_de/files/407910\\_BT\\_MekinistTafinlarFI.pdf](https://www.novartis.com/de-de/sites/novartis_de/files/407910_BT_MekinistTafinlarFI.pdf)



Arbeitsgemeinschaft  
Dermatologische Onkologie  
**ADO**

# **Dermato-Onkologie UPDATE 2024**

**14.–15.2.2025**  
im Novotel Berlin am Tiergarten  
**HYBRID MEETING**

**SAVE  
THE  
DATE**



**3.-5.  
APRIL  
2025**

**11<sup>TH</sup> WORLD CONGRESS  
OF MELANOMA AND  
21<sup>ST</sup> EADO CONGRESS**

Megaron Athens  
International Conference  
Centre  
Athens, Greece



Melanoma  
World Society  
**MWS**

**SAVE  
THE  
DATE**



[worldmelanoma2025.com](http://worldmelanoma2025.com)

# Together into the future

Plan with us your next  
scientific event



MedConcept Gesellschaft  
für medizinische Projekte mbH  
Friedenstraße 58, 15366 Neuenhagen



+49 3342 42689-30



info@medconcept.org



www.medconcept.org

**MEDCONCEPT**   
Experience since 1997

# Congress On-Demand

**All approved lectures from the EVENT will be available on the On-Demand platform 48 hours after the session until September 30, 2024.**

The on-demand service is available to all registered attendees (F2F and virtual).

**THE AREA  
IS PASSWORD  
PROTECTED**



Access to the On-Demand area is granted using the same login credentials as for the virtual platform.

# IMPORTANT INFORMATION

## Internet Connection

Free Wi-Fi service will be available to all delegates within the Hilton Hotel Munich Park.

**Network Name: Post-Chicago Meeting**

**Network password: Munich2024**

## Certificate of Attendance:

All registered attendees will receive a certificate of attendance within 10 days after the meeting via e-mail and after completing an evaluation survey.

**Please note!** If you need to change your contact e-mail address, please come to the registration desk.

## Name Badges

Name badges must be worn visibly at all times during the meeting and in the exhibition area.

## Daily Scan

To receive your daily CME credits please remember to scan yourself once a day at the registration desk.

German participants must also register in the barcode list of the Bavarian Medical Association.

## TED/Polling

Please scan the QR code with your mobile device or visit **www.slido.com** and enter the event code to participate in the polling.

### BALLROOM



event code  
#PC24Plenary

### RUMFORD



event code  
#PC24Parallel